Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
February 18, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 18, 2008
- Taiyo Completes Expansion of Its Production Facilities
February 18, 2008
- Aricept, Pariet/AcipHex Drive Eisai's Business
February 18, 2008
- Towa to Establish Overnight Delivery System via Network of Hansha
February 18, 2008
- Nobelpharma to Launch 3 New Drugs
February 18, 2008
- Survey／COPD Awareness Rate Remains Unchanged at 34%: NBI/Pfizer Survey
February 18, 2008
- Takara Bio to Launch World's First Protein Regulation System
February 18, 2008
- GENERICS NEWS IN BRIEF
February 18, 2008
- Korosho to Send Missions to the US, UK and France
February 18, 2008
- SELF-MEDICATION NEWS IN BRIEF
February 18, 2008
- JPMA to Cooperate in Reduction in CO2 Emission
February 18, 2008
- Requirements for Self-injection of IFN, Etanercept Relaxed
February 18, 2008
- BUSINESS NEWS IN BRIEF
February 18, 2008
- Kyushu Medical Association Decides to Support Dr Karasawa
February 18, 2008
- Herceptin Approved for Postoperative Adjuvant Chemotherapy
February 18, 2008
- Takeda to Use Amgen Japanas Development Subsidiary
February 18, 2008
- No Problems Found in EPPV of Velcade, Alimta
February 18, 2008
- Objection to Use of Literature by MRs without Obtaining Prior Consent
February 18, 2008
- REGULATORY NEWS IN BRIEF
February 18, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…